...
机译:错误:GLP GLP -1受体激动剂治疗对肥胖抗精神病治疗患者体重的影响:随机,安慰剂对照试验
Centre for Neuropsychiatric Schizophrenia Research CNSR and Center for Clinical Intervention and;
Centre for Neuropsychiatric Schizophrenia Research CNSR and Center for Clinical Intervention and;
Centre for Neuropsychiatric Schizophrenia Research CNSR and Center for Clinical Intervention and;
Centre for Neuropsychiatric Schizophrenia Research CNSR and Center for Clinical Intervention and;
Department of Clinical Physiology Nuclear Medicine &
PETRigshospitalet University of;
Departments of Clinical Biochemistry and Medicine Research Centre for Ageing and;
Novo Nordisk Foundation Centre for Basic Metabolic Research Faculty of Health and Medical;
Department of Clinical Medicine Faculty of Health and Medical SciencesUniversity of;
Centre for Neuropsychiatric Schizophrenia Research CNSR and Center for Clinical Intervention and;
机译:错误:GLP GLP -1受体激动剂治疗对肥胖抗精神病治疗患者体重的影响:随机,安慰剂对照试验
机译:GLP-1受体激动剂是否会改变抗精神病药物治疗患者的糖耐量?随机,双盲,安慰剂对照临床试验的设计
机译:用GLP-1受体激动剂治疗精神病相关的肥胖症-一项针对研究者发起的前瞻性,随机,安慰剂对照,双盲干预研究的协议:TAO研究方案
机译:多中心,安慰剂对照,双盲,随机研究口服Toceranib磷酸盐(Palladia TM,SU11654),受体酪氨酸激酶抑制剂,用于治疗经常性MAS的狗
机译:GLP-1受体激动剂Exendin-4通过β细胞和非β细胞机制改善了血糖控制。
机译:GLP-1受体激动剂治疗对肥胖抗精神病药物治疗的精神分裂症患者体重的影响:一项随机安慰剂对照试验
机译:错误:GLP -1受体激动剂治疗对肥胖抗精神病患者体重的影响:随机,安慰剂对照试验